logo
Surgical Staplers Market Size to Exceed USD 11.02 Bn by 2034

Surgical Staplers Market Size to Exceed USD 11.02 Bn by 2034

Yahoo06-05-2025

The surgical stapler market is undergoing a transformative phase, driven by technological innovations, rising surgical volumes, and increasing patient preference for less invasive treatment methods. The market, valued in the multi-billion-dollar range, has witnessed a noticeable shift from manual, reusable staplers to advanced powered and disposable variants. Hospitals and surgical centers are investing in state-of-the-art devices that enhance operational efficiency and patient safety.
Also Read: How the Surgical Procedures Market Is Shaping the Future of Healthcare
By end user, hospitals emerged as the largest segment, generating a maximum revenue share of around 68% in 2024, attributed to the high volume of surgical procedures conducted in hospital settings.
By type, the reusable surgical staplers segment led the market with a revenue share of approximately 62% in 2024, driven by cost-effectiveness and sustainability initiatives.
By technology, the manual surgical staplers segment contributed the highest revenue share, capturing over 59% of the market in 2024, owing to its widespread adoption across various surgical specialties.
North America accounted for the largest revenue share of 42% in 2024, firmly establishing its dominance in the global surgical staplers market.
The market is expected to grow at a CAGR of 6.72 % from 2025 to 2034.
It is projected to reach $11,020 million by 2034.
The surgical staplers market is valued at $6,140 million in 2025.
Surgical staplers are highly specialized medical instruments designed to deliver rapid, uniform, and secure closure of surgical wounds. They are increasingly replacing traditional sutures due to their ability to minimize surgical time, reduce infection risks, and enhance precision in complex procedures. Their application spans a wide range of surgeries, including gastrointestinal, thoracic, orthopedic, and cosmetic surgeries .
The Full Study is Readily Available | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/2216
Ottawa, May 06, 2025 (GLOBE NEWSWIRE) -- In terms of revenue, the surgical staplers market is worth USD 6.14 billion in 2025 and is anticipated to reach around USD 6.56 billion in 2026. The market is forecast to cross USD 11.02 billion by 2034 with a CAGR of 6.72% from 2025 to 2034. The North America surgical staplers industry size was valued at USD 2.42 billion in 2024 and is expanding at a CAGR of 6.75% during the forecast period.
According to Precedence Research, the global surgical staplers market size was valued at USD 6.14 billion in 2025 and is expected to exceed USD 11.02 billion by 2034, marking a strong CAGR of 6.72% from 2025 to 2034, driven by increasing adoption of minimally invasive surgeries and technological innovations.
Story Continues
Powered staplers, equipped with ergonomic designs and intelligent control systems, are rapidly replacing manual models, offering improved speed and consistency, especially in minimally invasive and robotically assisted surgeries. Moreover, the growing global prevalence of chronic diseases such as obesity, cancer, and cardiovascular ailments has increased the need for complex surgical interventions, further boosting demand. Key manufacturers are also focusing on customizable stapler solutions to match specific tissues, types, improve outcomes, and reduce post-surgical complications.
Also Read: Future of the Surgical Equipment Market: Innovations, Challenges, and Growth Opportunities
Surgical Staplers Market Key Trends
Surge in minimally invasive producers: The demand for laparoscopic and thoracoscopic surgeries is driving the adoption of surgical staplers, particularly powered and battery-operated variants.
Integration with robotic surgery platforms: Staplers compatible with robotic systems are gaining traction in high-precision procedures.
Innovation for disposable staplers: To reduce the risk of infection and meet stringent hygiene standards, healthcare facilities are opting for single-use stapling systems.
Expansion in emerging economies: Improved healthcare infrastructure and increased funding in regions such as Southeast Asia, the Middle East, and Africa are creating new opportunities for market players.
Also Read: Emerging Technologies Driving the Surgical Robotics Market Growth: Size, Trends, and Forecast to 2034
Limitations and Challenges
High initial investment: Advanced stapling devices and robotic-compatible systems can be costly, posing adoption barriers for smaller hospitals and under-resourced healthcare facilities.
Potential device malfunctions: Staple line leaks, misfires, and internal injuries can occur, particularly if the device is misused or of poor quality.
Stringent regulatory oversight: Products are subject to detailed approval processes by regulatory bodies like the FDA and EMA, which can delay product launches.
Post-surgical complications: In some cases, improper stapling can lead to infection, bleeding, or the need for revision surgery.
Training and skill requirements: Proper handling of powered staplers and robotic instruments demands adequate training, which may not be universally available.
Also Read: Advancements in Wound Closure Technologies: Surgical Sutures Market Analysis, Trends, and Forecast 2024–2034
Precision Under Development: The Evolving Craft of Surgical Stapling
The market for surgical staplers has evolved from basic mechanical tools to technologically advanced precision instruments. Leading manufacturers are investing in next-generation staplers that incorporate features such as AI-assisted control, tissue sensing feedback, and a multi-row stapling mechanism. These features help surgeons maintain greater control and accuracy, especially in complex, minimally invasive procedures.
The development of biocompatible and absorbable staples has opened new avenues in gastrointestinal and obstetric surgeries. Simultaneously, the increasing popularity of robotic-assisted surgeries has promoted the design of staplers that can be operated remotely via console-based systems, allowing for even finer control and reduced human error.
A recent research study revealed that the report offers a comprehensive review of the industry developments and trends influencing the growth of the surgical stapler market in Saudi Arabia. Additionally, it includes a detailed analysis and assessment of the Saudi Arabian surgical stapler market.
Government initiatives, especially in developing regions, are also contributing by improving healthcare infrastructure and access to advanced surgical tools, which are expected to significantly bolster market expansion in the coming years.
Surgical Staplers Market Report Coverage
Report Attribute
Key Statistics
CAGR
6.72%
Market Size in 2024
USD 5.75 Billion
Market Size in 2025
USD 6.14 Billion
Market Size by 2034
USD 11.02 Billion
Dominated Region
North America
Base Year
2024
Forecast Year
2025 to 2034
Segments Covered
Technology, Type, Product, Application, End User and Regions
Regions Covered
North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Set up a meeting at your convenience to get more insights instantly! https://www.precedenceresearch.com/schedule-meeting
How Big is the U.S. Surgical Staplers Market?
According to Precedence Research, the U.S. surgical staplers market size is calculated at USD 1.79 billion in 2025 and is expected to be worth USD 3.36 billion by 2034. The market is poised to grow at a CAGR of 7.24% from 2025 to 2034.
North America is the precision powerhouse
North America dominated the global surgical staplers market due to its advanced healthcare infrastructure, high surgical volumes, and continuous technological innovation. The region is at the forefront of adopting robotic-assisted surgeries and minimally invasive techniques, where powered staplers play a critical role. The presence of global medical device giants such as Medtronic, Johnson and Johnson, and Stryker ensures continuous product innovation and widespread distribution networks.
The rise in elective surgeries, a growing ageing population, and high incidence of chronic diseases like cancer and obesity also fuel the need for complex surgical interventions. Furthermore, the region's favorable reimbursement policies, government healthcare spending, and strong regulatory standards provide an enabling environment for market growth.
Top contributing country
United States: Leads the region with high R&D investment, a robust surgical ecosystem, and early adoption of innovative stapling technologies.
Canada: Known for its strong public healthcare system and rising demand for minimally invasive surgeries.
Asia-Pacific: The Rising Scalpel in the Global Market
Asia-Pacific is the fastest-growing region in the global surgical staplers market, owing to rapid urbanisation, population growth, and increasing healthcare awareness. Countries like China, India, Japan, and South Korea are significantly expanding their surgical care capabilities, backed by growing investments in hospital infrastructure and technological upgradation.
The region is witnessing a sharp increase in lifestyle-related diseases, leading to more bariatric, cardiovascular, and oncological surgeries. As a result, the demand for both disposable and powered staplers is rising rapidly. Moreover, international manufacturers are entering partnerships and expanding production facilities in Asia-Pacific to capitalise on cost efficiencies and emerging opportunities.
Also Read: Ambulatory Surgical Centers IT Solutions Market: Size, Emerging Technologies, and Future Outlook 2024–2034
Major Growth Factors contributing to market growth
Surge in Government Healthcare Initiatives: National healthcare schemes in India and China are expanding access to advanced surgical care.
Growing Medical Tourism: Countries like Thailand, Singapore, and Malaysia are emerging as top destinations for affordable surgeries.
Technological Adoption: Japan and South Korea are leading in the use of robotic surgery and precision stapling tools.
Expanding Middle-Class Population: Increased disposable income is motivating more patients to seek quality private healthcare.
Rising Chronic Disease Burden: The prevalence of diabetes, cancer, and cardiovascular diseases is driving up surgical volumes across the region.
Surgical Staplers Market Segmentation Analysis
By Technology Analysis:
The power-driven surgical stapler segment leads the market owing to its precision, reduced tissue trauma, and consistency in staple formation. These devices are particularly beneficial in minimally invasive procedures where access is limited and precision is critical. Surgeons prefer power staplers because they reduce manual fatigue and improve operative efficiency, especially in high-volume or complex surgeries like bariatric, gastrointestinal, and thoracic procedures. With the growing integration of robotic-assisted surgeries, powered staplers are increasingly becoming the standard in advanced healthcare facilities.
On the other hand, Manual surgical staplers, though basic in operation, are rapidly growing in demand due to their affordability, simplicity, and adaptability in low-resource settings. Emerging economies in Asia, Latin America, and Africa are heavily relying on manual staplers, particularly in public hospitals and rural healthcare centers. Their low maintenance, minimal training requirements, and effective performance make them an ideal choice in developing nations where healthcare access is still expanding.
Also Read: Driving Surgical Innovation: Minimally Invasive Surgical Instruments Market Analysis and Growth Forecast 2024–2034
By Type Analysis:
Disposable staplers dominate the market due to their reduced risk of cross-contamination and infection. These are preferred in critical surgical environments, especially in countries with strict hygiene protocols like the U.S., Canada, and Japan. They are highly adopted in emergency surgeries and infectious cases where patient safety is a priority. Their single-use nature ensures sterility and compliance with hospital infection control regulations, making them the first choice for many healthcare providers.
Moreover, the reusable stapler segment is witnessing rapid growth due to increased focus on cost-saving and sustainability. Hospitals and surgical centers are investing in sterilization systems, allowing safe reusability of stapling instruments. With healthcare systems increasingly moving towards green practices, reusable options offer long-term economic and environmental benefits. This trend is particularly strong in Europe and certain parts of Asia, where sustainable healthcare is gaining momentum.
By Application Analysis:
Abdominal and pelvic surgeries represent the leading application segment, with procedures such as colorectal surgery, gastrointestinal surgery, and gynecological operations heavily reliant on surgical staplers. These procedures often involve large tissue volumes and complex anatomies, making the precision and efficiency of staplers vital. The growing prevalence of colorectal cancer and obesity-related surgeries contributes to sustained demand in this segment.
Furthermore, Cardiac and thoracic surgeries are the fastest-growing application segment due to increased incidences of heart diseases, lung cancer, and the rise in open-heart surgeries. These procedures require high-performance stapling tools for critical areas like blood vessels and lung tissues. Innovations in vascular staplers and an increasing trend towards minimally invasive cardiac surgeries are driving growth in this space.
Also Read: Lung Cancer Therapeutics Market Report: Emerging Therapies, Competitive Landscape, and Forecast to 2034
By End User Analysis:
Hospitals dominate the end-user segment as they perform the bulk of complex and high-risk surgeries requiring advanced surgical stapling tools. Equipped with skilled personnel, ICU support, and advanced operating theatres, hospitals are the primary adopters of both disposable and powered staplers. Government and private hospital networks in countries like the U.S., China, and Germany are consistently investing in surgical infrastructure, maintaining dominance in this segment.
On the other hand, Ambulatory Surgical Centers (ASCs) are witnessing the fastest growth due to the rising demand for cost-effective, short-stay surgical procedures. ASCs are ideal for minor and medium-complexity surgeries and are gaining popularity for their operational efficiency, reduced costs, and shorter patient recovery times. As health systems shift towards outpatient care models, ASCs are increasingly adopting surgical staplers for procedures in orthopedics, gynecology, and general surgery.
Related Topics You May Find Useful:
High Speed Surgical Drill Market Size accounted for USD 632.60 million in 2024 and is predicted to reach around USD 922.54 million by 2034, growing at a CAGR of 3.85% from 2024 to 2034.
Surgical Snare Market Size accounted for USD 2.27 billion in 2024 and is expected to exceed around USD 3.34 billion by 2034, growing at a CAGR of 3.96% from 2024 to 2034.
Surgical Retractor Market Size was accounted for USD 2.40 billion in 2024, and is expected to reach around USD 4.49 billion by 2034, expanding at a CAGR of 6.46% from 2025 to 2034.
Next Generation Surgical Robotics Market is expected to be valued at USD 4.54 billion in 2024 and is anticipated to reach around USD 90.00 billion by 2034, expanding at a CAGR of 34.81% over the forecast period from 2024 to 2034.
Surgical Tables Market Size is estimated at USD 1.29 billion in 2024 and is anticipated to reach around USD 1.85 billion by 2034, expanding at a CAGR of 3.70% from 2024 to 2034.
Surgical Staplers Market Key Players
3M Company
Becton
AesDex, LLC
B. Braun Melsungen AG (Germany)
Becton Dickinson
CareFusion Corporation
Codman & Shurtleff (Codman)
Conmed Corporation
Covidien plc
CryoLife Inc.
Dextera Surgical Inc. (U.S.)
Dickinson and Company (U.S.)
Ethicon Endo-Surgery, Inc.
Frankenman International Limited (Honk Kong)
Grena Ltd. (U.K.)
Integra LifeSciences Corporationm
Intuitive Surgical Inc. (U.S.)
Johnson & Johnson Services, Inc.
Medtronic (Ireland)
Meril Life Science Pvt. Ltd.
Purple Surgical Holdings Limited
Reach Surgical Inc. (China)
Smith & Nephew (U.K.)
Stryker Corporation
Surkon Medical
Touchstone International Medical Science Co. Ltd.,
Victor Medical Instruments
Welfare Medical Ltd. (UK)
Zimmer Holdings, Inc.
Recent development
In May 2025, Intuitive Surgical has obtained clearance from the Food and Drug Administration (FDA) for its da Vinci Single Port surgical system, specifically for procedures that can be performed through the anus. This clearance enables the system to be used for transanal local excision and resection, allowing physicians to access lesions in the upper rectum without the need for abdominal incisions. Traditionally, a transabdominal rectal resection involves multiple incisions and may necessitate the removal of the rectum.
The Surgical Staplers Market report is categorized into the following segments and subsegments:
By Technology
Manual
Powered
By Type
Disposable
Reusable
By Application
Abdominal & Pelvic Surgery
General Surgery
Cardiac and Thoracic Surgery
Orthopaedic Surgery
Other Surgical Applications
By End User
Hospitals
Ambulatory Surgical Centres (ASCs) and Clinics
By Geography
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa (MEA)
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or Asia Pacific.
Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2216
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344
Precedence Research offers exclusive subscription services designed to provide in-depth data and analytics insights. With a subscription, you gain access to a comprehensive suite of statistical resources, market intelligence, and research tools tailored to your business needs. Whether you're looking for industry trends, competitive analysis, or future market projections, our subscription plans ensure you stay ahead with reliable, up-to-date information.
Browse Our Subscription Plans@ https://www.precedenceresearch.com/get-a-subscription
About Us
Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
Web: https://www.precedenceresearch.com
Our Trusted Data Partners:
Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Nova One Advisor |
Get Recent News:
https://www.precedenceresearch.com/news
For Latest Update Follow Us:
LinkedIn | Facebook | Twitter

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Business Upturn

timean hour ago

  • Business Upturn

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Electric Motors Market Share Expected to Grow $206.4 Billion by 2029
Electric Motors Market Share Expected to Grow $206.4 Billion by 2029

Yahoo

time6 hours ago

  • Yahoo

Electric Motors Market Share Expected to Grow $206.4 Billion by 2029

Delray Beach, FL, June 01, 2025 (GLOBE NEWSWIRE) -- The global Electric Motors Market share is expected to grow from USD 152.2 billion in 2024 to USD 206.4 billion by 2029, at a CAGR of 6.3% during forecast period. Electric motors market is driven mainly by Increasing demand for HVAC systems among residential, commercial, and industrial end-users, growing demand for electric motors in manufacturing industries, and rising demand for energy-efficient motors. The electric motor market has bloomed forth globally. All these sectors inherit demanding environments for solving problems and improving reliability. From electric vehicles to industrial machinery, consumer electronics to wind turbines, electric motors find applications in many areas. They not only ensure low energy consumption but also increase efficiency and reduce operating costs. As the world population grows and economies expand, the demand for energy, particularly oil and gas, continues to rise. Increasing demand for HVAC (Heating, Ventilation, and Air Conditioning) systems among residential, commercial, and industrial end-users, industries shift towards energy-efficient electric motors due to lowered energy utilization and operational costs in manufacturing industries are some of the major driving factors for the electric motors market. Download PDF Brochure: List of Key Players in Electric Motors Market: ABB (Switzerland) Siemens (Germany) WEG (Brazil) Wolong Electric (China) NIDEC CORPORATION (Japan) Drivers, Opportunities and Challenges in Electric Motors Market: Driver: Increasing demand for HVAC systems in residential, commercial, and industrial sectors Restraint: Fluctuating prices of raw materials Opportunity: Transition in the global automotive industry toward electric vehicles Challenge: Shortage of components and supply chain issues Electric mobility is making a huge transition in the global automobile industry. The proactive efforts for the decarbonization of society in Europe are driven by the ever-increasing share of electric motors in the market. Advancements in battery technologies have reduced costs of batteries and improved the charging speed of the batteries. The increase in government support by providing redemptions on tax and incentives for promoting eco-friendly electric vehicles through electric motors are also acts of opportunities for the growth of the electric motors market. As per the IEA, it is revealed that 50% of global passenger electric vehicles should come from China in the year 2025. Many governments worldwide are implementing policies and incentives to promote the adoption of electric vehicles as part of efforts to reduce greenhouse gas emissions and combat climate change. These policies include subsidies for EV purchases, tax incentives, and stricter emissions regulations, all of which are accelerating the transition to electric mobility and, consequently, increasing demand for electric vehicle motor market. The rapid growth of the EV market has led to the construction of new manufacturing facilities dedicated to producing electric vehicles and their components, including electric motors. Major automakers and new EV startups are investing heavily in scaling up production, which includes securing a reliable supply of electric motors. the growing demand for electric vehicles is a major driver of demand for electric motors. The transition to electric mobility, driven by technological advancements, government policies, and consumer preferences, is creating a significant and expanding market for electric motors across a wide range of vehicle types and applications. As the EV market continues to grow, the demand for efficient, powerful, and innovative electric motors will remain strong.. Request Sample Pages: Asia Pacific region to be the largest electric motors market Asia Pacific is expected to dominate the global electric motor market size between 2024–2029, followed by Europe and North America. The urban population growth drives demand for infrastructure, including commercial buildings, residential complexes, and public utilities, all of which rely heavily on electric motors for HVAC systems, elevators, water treatment, etc are the reasons for the region's significant market size. Countries such as China and India are driving demand, supported by government initiatives promoting industrial automation and renewable energy adoption. The region's large water treatment plants and increasing electric vehicle manufacturing add to the demand for high-power motors. Moreover, improving motor efficiency and compact high-density designs also increase the market further. This is driving the electric motor market size in the Asia Pacific region. Related Reports: Brushless DC Motor Market - Global Forecast to 2028 Energy Efficient Motor Market - Global Forecast to 2028 CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website:

Electric Motors Market Share Expected to Grow $206.4 Billion by 2029
Electric Motors Market Share Expected to Grow $206.4 Billion by 2029

Yahoo

time6 hours ago

  • Yahoo

Electric Motors Market Share Expected to Grow $206.4 Billion by 2029

Delray Beach, FL, June 01, 2025 (GLOBE NEWSWIRE) -- The global Electric Motors Market share is expected to grow from USD 152.2 billion in 2024 to USD 206.4 billion by 2029, at a CAGR of 6.3% during forecast period. Electric motors market is driven mainly by Increasing demand for HVAC systems among residential, commercial, and industrial end-users, growing demand for electric motors in manufacturing industries, and rising demand for energy-efficient motors. The electric motor market has bloomed forth globally. All these sectors inherit demanding environments for solving problems and improving reliability. From electric vehicles to industrial machinery, consumer electronics to wind turbines, electric motors find applications in many areas. They not only ensure low energy consumption but also increase efficiency and reduce operating costs. As the world population grows and economies expand, the demand for energy, particularly oil and gas, continues to rise. Increasing demand for HVAC (Heating, Ventilation, and Air Conditioning) systems among residential, commercial, and industrial end-users, industries shift towards energy-efficient electric motors due to lowered energy utilization and operational costs in manufacturing industries are some of the major driving factors for the electric motors market. Download PDF Brochure: List of Key Players in Electric Motors Market: ABB (Switzerland) Siemens (Germany) WEG (Brazil) Wolong Electric (China) NIDEC CORPORATION (Japan) Drivers, Opportunities and Challenges in Electric Motors Market: Driver: Increasing demand for HVAC systems in residential, commercial, and industrial sectors Restraint: Fluctuating prices of raw materials Opportunity: Transition in the global automotive industry toward electric vehicles Challenge: Shortage of components and supply chain issues Electric mobility is making a huge transition in the global automobile industry. The proactive efforts for the decarbonization of society in Europe are driven by the ever-increasing share of electric motors in the market. Advancements in battery technologies have reduced costs of batteries and improved the charging speed of the batteries. The increase in government support by providing redemptions on tax and incentives for promoting eco-friendly electric vehicles through electric motors are also acts of opportunities for the growth of the electric motors market. As per the IEA, it is revealed that 50% of global passenger electric vehicles should come from China in the year 2025. Many governments worldwide are implementing policies and incentives to promote the adoption of electric vehicles as part of efforts to reduce greenhouse gas emissions and combat climate change. These policies include subsidies for EV purchases, tax incentives, and stricter emissions regulations, all of which are accelerating the transition to electric mobility and, consequently, increasing demand for electric vehicle motor market. The rapid growth of the EV market has led to the construction of new manufacturing facilities dedicated to producing electric vehicles and their components, including electric motors. Major automakers and new EV startups are investing heavily in scaling up production, which includes securing a reliable supply of electric motors. the growing demand for electric vehicles is a major driver of demand for electric motors. The transition to electric mobility, driven by technological advancements, government policies, and consumer preferences, is creating a significant and expanding market for electric motors across a wide range of vehicle types and applications. As the EV market continues to grow, the demand for efficient, powerful, and innovative electric motors will remain strong.. Request Sample Pages: Asia Pacific region to be the largest electric motors market Asia Pacific is expected to dominate the global electric motor market size between 2024–2029, followed by Europe and North America. The urban population growth drives demand for infrastructure, including commercial buildings, residential complexes, and public utilities, all of which rely heavily on electric motors for HVAC systems, elevators, water treatment, etc are the reasons for the region's significant market size. Countries such as China and India are driving demand, supported by government initiatives promoting industrial automation and renewable energy adoption. The region's large water treatment plants and increasing electric vehicle manufacturing add to the demand for high-power motors. Moreover, improving motor efficiency and compact high-density designs also increase the market further. This is driving the electric motor market size in the Asia Pacific region. Related Reports: Brushless DC Motor Market - Global Forecast to 2028 Energy Efficient Motor Market - Global Forecast to 2028 CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store